SZShengyu Zhou

Shengyu Zhou

*This is an algorithmically generated author record based on publicly available information.

Shengyu Zhou has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Lin Gui

    Department of Informatics, Kings College London, London, U.K.

    2 shared publications
  • PengFei Liu

    Department of Radiology The First Affiliated Hospital of Soochow University, The Fourth Affiliated Hospital of Soochow University Suzhou Jiangsu Province China

    2 shared publications
  • Yan Qin

    Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China

    2 shared publications
  • Yuankai Shi

    Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    2 shared publications
  • Baoxia Sun

    Infectious Department

    1 shared publication
  • Changgong Zhang

    Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China

    1 shared publication

Latest Publications

  • Open Access

    Genomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study

    by Yue Li, Baoming Wang, Chunyang Wang, Dandan Zhao, Zhengchuang Liu, Yanling Niu, Xiaojuan Wang, Wei Li, Jianhua Zhu, Houquan Tao, et al.

    Background: In contrast to Caucasian melanoma, which has been extensively studied, there are few studies on melanoma in Asian populations. Sporadic studies reported that only 40% of Asian melanoma patients could be druggable, which was much lower than that in Caucasians. More studies are required to refine this conclusion. Methods: Chinese melanoma patients (n = 469) were sequentially sequenced by DNA-NGS and RNA-NGS. The genomic alterations were determined, and potentially actionable targets were investigated. Results: Patients with potential druggable targets were identified in 75% of Chinese melanoma patients by DNA-NGS based on OncoKB, which was much higher than in a previous Asian study. NRG1 fusions were first identified in melanoma. In addition, up to 11.7% (7/60) of patients in the undruggable group could be recognized as actionable by including RNA-NGS analysis. By comparing the fusion detection rate between DNA-NGS and RNA-NGS, all available samples after DNA-NGS detection were further verified by RNA-NGS. The use of RNA-NGS enhanced the proportion of druggable fusions from 2.56% to 17.27%. In total, the use of RNA-NGS increased the druggable proportion from 75% to 78%. Conclusions: In this study, we systemically analyzed the actionable landscape of melanoma in the largest Asian cohort. In addition, we first demonstrated how DNA and RNA sequential sequencing is essential in bringing clinical benefits to more patients with melanoma.


  • A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma

    by Yunxia Tao, Haizhu Chen, Yu Zhou, Xiaohu He, Yan Qin, Peng Liu, Shengyu Zhou, Jianliang Yang, Liqiang Zhou, Changgong Zhang, et al.

    We aimed to develop a new risk stratification tool to predict freedom from progression (FFP) for newly diagnosed advanced classical Hodgkin lymphoma (cHL). We collected data from 386 patients with advanced cHL diagnosed between December 8, 2000 and October 29, 2018, and treated with curative intent with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or an ABVD-equivalent regimen. Cases were randomly divided into training and validation cohorts at a ratio of 7:3. The new model was constructed based on the results of Cox proportional hazards model in the training cohort. Comparisons of discrimination between the new model and other models in the training and validation cohorts for FFP prediction were measured by time-dependent area under curve (tAUC) and Harrell's C-index. Calibration plots were constructed to compare the consistency between the predicted and observed estimates of survival probability for the new model in the training and validation cohorts. The new model (IPSPLR) composed of International Prognostic Score (IPS)-3 and platelet/lymphocyte ratio (PLR) provided four distinct risk groups. The IPSPLR showed better discriminative ability when compared with IPS-3 and IPS-7. The AUC of IPSPLR was consistently higher than that of IPS-3 and IPS-7 between 12 and 120 months. The C-index of the IPSPLR was higher than that of IPS-7 and IPS-3. The calibration plots showed an excellent agreement between the IPSPLR-predicted and observed estimates of 5-year FFP. The IPSPLR is an easily used tool for FFP prediction for newly diagnosed advanced cHL. Validation of this tool in other large datasets is needed.


  • Open Access

    Micronutrient Level Is Negatively Correlated with the Neutrophil‐Lymphocyte Ratio in Patients with Severe COVID‐19

    by Shengyu Zhou, Fayan Zhang, Fangfang Chen, Peng Li, Yujie He, Julong Wu, Liang Dong, Chunting Wang, Ximing Wang, Wei Zhang, et al.

    Aim. To explore the potential relationship between NLR and micronutrient deficiency in patients with severe COVID‐19 infection. Methods. Sixteen patients were categorized into the mild group (mild COVID‐19) and severe group (severe COVID‐19) based on the guideline of the management of COVID‐19. The lactate dehydrogenase (LDH); superoxide dismutase (SOD), the inflammatory markers (neutrophil lymphocyte ratio (NLR)), erythrocyte sedimentation rate (ESR), c‐reactive protein (CRP), selenium (Se), iron (Fe), zinc (Zn), nickel (Ni), copper (Cu), chromium (Cr), cadmium (Cd), arsenic (As), and manganese (Mn) were measured in the blood. Results. Compared to the mild group, the NLR (P < 0.05) and the level of Se (P < 0.01), Fe (P < 0.05), and Zn (P < 0.05) were significantly decreased in the severe group. The level of Se, Fe, and Zn was significantly correlated to NLR levels. Furthermore, close positive correlation was found between NLR and severity of COVID‐19. Conclusion. The micronutrient deficiency in the blood is associated with NLR in the severity of COVID‐19 patients.


  • Open Access

    A RETROSPECTIVE ANALYSIS OF REAL‐WORLD OUTCOMES OF CHINESE ELDER PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

    by P. Liu, Y. Han, S. Jiang, X. He, Y. Qin, L. Gui, S. Zhou, L. Zhou, J. Yang, S. Yang, et al.